CCND1 and cancer: Dysregulation of the CDK4/6-Rb pathway, as with the activation of CCND1/CDK4 or CDKN2A loss, contributes to cancer development and confers resistance of cancer cells to treatment with the MAPK/ERK inhibitors [53].